following an abbreviated submission:
rufinamide (Inovelon®) is accepted for restricted use within NHSScotland.
Indication under review: as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 1 years to <4 years.
SMC restriction: restricted to use in patients who have failed treatment with or are intolerant of other antiepileptic drugs.
Rufinamide (Inovelon®) has previously been accepted for restricted use in adults and children aged ≥4 years. The licence has been extended to include children aged 1 year to <4 years.
Download detailed advice362KB (PDF)
Medicine details
- Medicine name:
- rufinamide (Inovelon)
- SMC ID:
- SMC2146
- Indication:
as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 1 years of age and older
- Pharmaceutical company
- Eisai Ltd
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 08 April 2019
This preparation has been discontinued but generic versions of the medicine remain available.